TY - JOUR T1 - Genetically determined body mass index mediates the effect of smoking on type 2 diabetes risk, but not coronary artery disease risk JF - medRxiv DO - 10.1101/2020.01.30.20019737 SP - 2020.01.30.20019737 AU - Christopher S Thom AU - Zhuoran Ding AU - Michael G Levin AU - Scott M Damrauer AU - Benjamin F Voight Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/04/30/2020.01.30.20019737.abstract N2 - Clinical observations have linked tobacco smoking with increased type 2 diabetes risk (1–5), a major public health concern (6). Mendelian randomization analysis has recently suggested smoking may be a causal risk factor for type 2 diabetes (7). However, this initial association could be mediated by additional causal risk factors correlated with smoking behavior, which have not been investigated to date. We hypothesized that body mass index (BMI) could explain the association between smoking and diabetes risk. First, we confirmed previous reports that genetically determined smoking behavior increased risk for both type 2 diabetes (OR=1.21, 95% CI: 1.15-1.27, P=1×10−12) and coronary artery disease (CAD; OR=1.21, 95% CI: 1.16-1.26, P=2×10−20). Additionally, a 2-fold increased smoking risk is positively associated with body mass index (BMI; ∼0.8 kg/m2, 95% CI: 0.54-0.98 kg/m2, P=1.8×10−11). In multivariable Mendelian randomization analysis, including BMI accounted for nearly all of the risk of smoking on type 2 diabetes (OR 1.06, 95% CI: 1.01-1.11, P=0.03). In contrast, the independent association between smoking and CAD persisted (OR 1.12, CI: 1.08-1.17, P=3×10−8) despite controlling for BMI. Causal mediation analyses agreed with these estimates. Our findings support a model whereby smoking initiation increases obesity, which in turn increases type 2 diabetes risk, with minimal if any direct effects from smoking on diabetes risk. Patients should be advised to stop smoking to limit both type 2 diabetes and CAD risk, and therapeutic efforts should consider pathophysiology relating smoking and obesity.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by National Institutes of Health [DK101478 and HG010067 to BFV, HD043021 to CST], an American Academy of Pediatrics Marshall Klaus Neonatal-Perinatal Research Award to CST, and a Linda Pechenik Montague Investigator Award to BFV. SMD is supported by the US Department of Veterans Affairs, Clinical Science Research and Development (IK2-CX001780). This publication does not represent the views of the Department of Veterans Affairs or the US Government. All authors confirm independence from funders and that all authors had full access to all of the statistics in the study. As such they can attest to the integrity of the data and the accuracy of the data analysis.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used for this work utilize summary data that is available in the public domain. ER -